✉ Email this page to a colleague
« Back to Dashboard
AZD5363 is an investigational drug.
There have been 30 clinical trials for AZD5363. The most recent clinical trial was a Phase 2 trial, which was initiated on June 25th 2019.
The most common disease conditions in clinical trials are Breast Neoplasms, Neoplasms, and Prostatic Neoplasms. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Cancer Research UK.
There are one hundred and thirty-four US patents protecting this investigational drug and one international patent.
Recent Clinical Trials for AZD5363
|Capivasertib China PK Study||AstraZeneca||Phase 1|
|A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer||Daiichi Sankyo Company, Limited||Phase 1|
|A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer||AstraZeneca||Phase 1|
Top disease conditions for AZD5363
Top clinical trial sponsors for AZD5363
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|AZD5363||See Plans and Pricing||Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity||The University of North Carolina at Chapel Hill (Chapel Hill, NC)||See Plans and Pricing|
|AZD5363||See Plans and Pricing||Treatment of ophthalmic conditions by selectively removing senescent cells from the eye||Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN)||See Plans and Pricing|
|AZD5363||See Plans and Pricing||Polymeric nanoparticles and methods of making and using same||Merck Sharp & Dohme Corp. (Rahway, NJ) Pfizer Inc. (New York, NY)||See Plans and Pricing|
|AZD5363||See Plans and Pricing||Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide||AstraZeneca AB (Sodertalje, SE)||See Plans and Pricing|
|AZD5363||See Plans and Pricing||7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]- pyrimidin-5 (1h)-one, salts thereof and methods of using the same in combination therapy||Oncoceutics, Inc. (Philadelphia, PA)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|AZD5363||Australia||AU2015244171||2034-04-11||See Plans and Pricing|
|AZD5363||Australia||AU2015244179||2034-04-11||See Plans and Pricing|
|AZD5363||Canada||CA2945128||2034-04-11||See Plans and Pricing|
|AZD5363||Canada||CA2945129||2034-04-11||See Plans and Pricing|
|AZD5363||China||CN106414451||2034-04-11||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|